caa a22 4500 445336315 CHVBK 20180317142756.0 cr unu---uuuuu 170323e20110801xx s 000 0 eng 10.1245/s10434-011-1587-5 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1587-5 Association of Elevated HIF-2α Levels with Low Beclin 1 Expression and Poor Prognosis in Patients with Chondrosarcoma [Elektronische Daten] [Changbao Chen, Qingjun Ma, Xinlong Ma, Zhongjun Liu, Xiaoguang Liu] Background: Hypoxia inducible factor (HIF)-2α is an important transcription factor that contributes to tumor proliferation and progression. Beclin 1 is a key mediator of autophagy, and dysfunction of Beclin 1 is implicated in tumorigenicity. This study was designed to investigate the expression patterns of HIF-2α and Beclin 1 and to clarify their clinical significance in chondrosarcoma. Methods: The mRNA and protein levels of HIF-2α and Beclin 1 in chondrosarcoma and the corresponding nontumor tissues were analyzed by real-time polymerase chain reaction and Western blot, respectively. The protein expression of HIF-2α and Beclin 1 was investigated by immunohistochemistry, and their associations with clinicopathological factors and overall survival were evaluated. Results: HIF-2α was remarkably elevated, whereas Beclin 1 was significantly reduced in chondrosarcoma compared with the corresponding nontumor tissues. High HIF-2α level and negative Beclin 1 expression were 52.9% and 58.8% in chondrosarcoma specimens, respectively. HIF-2α and Beclin 1 were associated with histological grade and Musculoskeletal Tumor Society stage. There was a significant inverse relationship between HIF-2α and Beclin 1. HIF-2α and Beclin 1 had significant impacts on the prognosis of chondrosarcoma patients. Multivariate analysis revealed that Beclin 1 was an independent prognostic factor for overall survival of patients with chondrosarcoma. Conclusions: Elevated HIF-2α levels assocaited with low Beclin 1 expression play a role in the development of chondrosarcoma. Beclin 1 can serve as a novel biomarker to predict survival of chondrosarcoma patients, and may represent a potential therapeutic target. Society of Surgical Oncology, 2011 Chen Changbao Department of Orthopaedic Surgery, Tianjin Hospital, Tianjin, China aut Ma Qingjun Department of Orthopaedic Surgery, Peking University Third Hospital, Beijing, China aut Ma Xinlong Department of Orthopaedic Surgery, Tianjin Hospital, Tianjin, China aut Liu Zhongjun Department of Orthopaedic Surgery, Peking University Third Hospital, Beijing, China aut Liu Xiaoguang Department of Orthopaedic Surgery, Peking University Third Hospital, Beijing, China aut Annals of Surgical Oncology Springer-Verlag 18/8(2011-08-01), 2364-2372 1068-9265 18:8<2364 2011 18 10434 https://doi.org/10.1245/s10434-011-1587-5 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1587-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Chen Changbao Department of Orthopaedic Surgery, Tianjin Hospital, Tianjin, China aut NATIONALLICENCE 700 1- Ma Qingjun Department of Orthopaedic Surgery, Peking University Third Hospital, Beijing, China aut NATIONALLICENCE 700 1- Ma Xinlong Department of Orthopaedic Surgery, Tianjin Hospital, Tianjin, China aut NATIONALLICENCE 700 1- Liu Zhongjun Department of Orthopaedic Surgery, Peking University Third Hospital, Beijing, China aut NATIONALLICENCE 700 1- Liu Xiaoguang Department of Orthopaedic Surgery, Peking University Third Hospital, Beijing, China aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/8(2011-08-01), 2364-2372 1068-9265 18:8<2364 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer